G1 Therapeutics (NASDAQ:GTHX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.
According to Zacks, “G1 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel, small-molecule therapies which address significant unmet needs in the treatment of cancer. The company’s product pipeline consists of CDK4/6, Trilaciclib (G1T28), G1T38 and G1T48. G1 Therapeutics, Inc. is based in Research Triangle Park, NC. “
Several other analysts have also recently commented on the company. JPMorgan Chase & Co. boosted their price target on G1 Therapeutics to $30.00 in a research report on Monday. BidaskClub cut G1 Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, February 3rd. BTIG Research began coverage on G1 Therapeutics in a report on Tuesday, December 19th. They issued a “buy” rating and a $38.00 target price for the company. Finally, Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Wednesday, November 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. G1 Therapeutics presently has an average rating of “Buy” and an average price target of $32.80.
G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings results on Wednesday, November 8th. The company reported ($0.55) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.01. sell-side analysts predict that G1 Therapeutics will post -2.72 EPS for the current year.
In other G1 Therapeutics news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $20.01, for a total value of $4,002,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Fredric N. Eshelman purchased 250,000 shares of the stock in a transaction dated Monday, November 13th. The shares were acquired at an average price of $19.73 per share, with a total value of $4,932,500.00. The disclosure for this purchase can be found here. Over the last 90 days, insiders sold 546,682 shares of company stock valued at $10,865,628.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in GTHX. FMR LLC purchased a new position in shares of G1 Therapeutics during the 2nd quarter worth $34,093,000. Vanguard Group Inc. purchased a new position in shares of G1 Therapeutics during the 2nd quarter worth $1,291,000. Goldman Sachs Group Inc. purchased a new position in shares of G1 Therapeutics during the 2nd quarter worth $1,144,000. Bank of New York Mellon Corp purchased a new position in shares of G1 Therapeutics during the 3rd quarter worth $568,000. Finally, Emerald Advisers Inc. PA grew its holdings in shares of G1 Therapeutics by 2.5% during the 3rd quarter. Emerald Advisers Inc. PA now owns 728,433 shares of the company’s stock worth $18,131,000 after purchasing an additional 17,977 shares during the period. Institutional investors and hedge funds own 43.25% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/08/g1-therapeutics-gthx-stock-rating-lowered-by-zacks-investment-research.html.
G1 Therapeutics Company Profile
G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.